Quantcast

Latest Tyrosine kinase receptors Stories

2010-04-30 13:34:00

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois. Designed to specifically inhibit ErbB3 signaling in ErbB2 over-expressing cancer cells, MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it from activating the phosphatidylinositol 3-kinase...

2010-04-21 06:22:57

WASHINGTON, D.C. "” Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21. The goal of the study led by Christopher Li, M.D., Ph.D., an associate member of the Epidemiology Program at the Fred Hutchinson Cancer Research Center, Seattle, was to discover and validate blood...

2010-04-20 08:42:55

Stanford University School of Medicine researchers have identified several small molecules that mimic a key but cumbersome protein in the brain, a discovery that could open the door to new therapies for a variety of brain disorders. The protein, designated by the acronym BDNF, is known to be involved in important brain functions that include memory and learning. "These small molecules could be the basis of drugs that provide entirely new avenues of treatment for a large number of...

2010-04-20 08:22:58

Altered expression and/or function of the protein BDNF, which promotes nerve cell survival, generation, and function, have been implicated in several neurodegenerative conditions, including Alzheimer disease. Although several properties of BDNF preclude its therapeutic application, it has been suggested that molecules that stimulate the protein to which BDNF binds, TrkB, might have therapeutic potential. Now, a team of researchers, led by Frank Longo, at Stanford University School of...

2010-02-22 06:00:00

CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(®) (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121. MM-121, Merrimack's lead oncology...

2010-02-16 08:46:36

A team of researchers, led by Patrick Mehlen, at Universit© de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma "” the most frequent solid tumor in young children"” by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks. In the study, NT-3 was found to be expressed at increased levels in aggressive human...

2010-02-13 09:07:12

The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement "“ a key element of cancer spread or metastasis, said Baylor College of Medicine (www.bcm.edu) researchers and collaborators in a report that appears in the current issue of the journal Molecular Cell....

2010-01-20 13:17:43

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth. In a related finding, they also proved that a particular EGFR mutation is important not only to initiate the tumor, but for its continued...

c36ecab30e0eeb2f545b7c4a4464b3bd1
2010-01-19 11:49:25

Researchers at the University of Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand binding domain of a vascular endothelial growth factor (VEGF) receptor in complex with one of its ligands (VEGF-C). Cancer cells require access to blood and lymph vessels for invasive growth and metastasis. By releasing VEGFs, cancer cells stimulate the surrounding blood vessels to invade the cancerous tumor mass. Blocking this...

2009-11-18 11:51:00

MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The reported results demonstrate that...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related